Advanced search
Publication Cover
Leukemia & Lymphoma Volume 65, 2024 - Issue 5
Submit an article Journal homepage
483
Views
0
CrossRef citations to date
0
Altmetric
Original Articles

Phase 1/2 multicenter trial of acalabrutinib in Chinese patients with relapsed/refractory mantle cell lymphoma

Yuqin Songa Department of Lymphoma, Peking University Cancer Hospital & Institute, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing, China
,
Jianyong Lib Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
,
Keshu Zhouc Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China
,
Xiaoyan Ked Department of Hematology, Peking University Third Hospital, Beijing, China
,
Zhen Caie Department of Hematology, the First Affiliated Hospital of Medical College, Zhejiang University, Hangzhou, China
,
Huilai Zhangf Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
,
Tingting Yaog AstraZeneca, Shanghai, China
,
Zhen Xiag AstraZeneca, Shanghai, China
,
Yiqiu Wangg AstraZeneca, Shanghai, China
,
Peiqiong Laig AstraZeneca, Shanghai, China
,
Xiaofeng Liug AstraZeneca, Shanghai, China
&
Jun Zhua Department of Lymphoma, Peking University Cancer Hospital & Institute, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing, ChinaCorrespondence[email protected]
 show all
Pages 647-652 | Received 20 Jul 2023, Accepted 21 Jan 2024, Published online: 01 Apr 2024

References

  • Jain P, Wang ML. Mantle cell lymphoma in 2022–a comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments. Am J Hematol. 2022;97(5):638–656. doi:10.1002/ajh.26523
  • Liu W, Liu J, Song Y, et al. Burden of lymphoma in China, 2006-2016: an analysis of the global burden of disease study 2016. J Hematol Oncol. 2019;12(1):115. doi:10.1186/s13045-019-0785-7
  • Yang QP, Zhang WY, Yu JB, et al. Subtype distribution of lymphomas in southwest China: analysis of 6,382 cases using WHO classification in a single institution. Diagn Pathol. 2011;6(1):77. doi:10.1186/1746-1596-6-77
  • Li X, Li G, Gao Z, et al. The relative frequencies of lymphoma subtypes in China: a nationwide study of 10002 cases by the Chinese lymphoma study group [abstract 169]. Ann Oncol. 2011;22(Suppl 4):iv141.
  • Sun J, Yang Q, Lu Z, et al. Distribution of lymphoid neoplasms in China: analysis of 4,638 cases according to the World Health Organization classification. Am J Clin Pathol. 2012;138(3):429–434. doi:10.1309/AJCP7YLTQPUSDQ5C
  • Cortelazzo S, Ponzoni M, Ferreri AJ, et al. Mantle cell lymphoma. Crit Rev Oncol Hematol. 2012;82(1):78–101. doi:10.1016/j.critrevonc.2011.05.001
  • Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507–516. doi:10.1056/NEJMoa1306220
  • Wang M, Rule S, Zinzani PL, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2018;391(10121):659–667. doi:10.1016/S0140-6736(17)33108-2
  • Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020;395(10232):1278–1291. doi:10.1016/S0140-6736(20)30262-2
  • Calquence [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals; 2022 August 2022.
  • Ghia P, Pluta A, Wach M, et al. ASCEND: phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2020;38(25):JCO2300838–2861.
  • Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–3068. doi:10.1200/JCO.2013.54.8800
  • Zhu J, Song Y, Li J, et al. editors. Pharmacokinetics, safety, and efficacy of acalabrutinib in chinese patients with relapsed/refractory mantle cell lymphoma and other B-cell malignancies: an open-label, multicenter phase 1/2 trial [poster 2892]. Annual Meeting and Exposition of the American Society of Hematology; 2022 10-13 December 2022; New Orleans, LA, USA.
  • Wang ML, Blum KA, Martin P, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015;126(6):739–745. doi:10.1182/blood-2015-03-635326
  • Tam CS, Opat S, Simpson D, et al. Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. Blood Adv. 2021;5(12):2577–2585. doi:10.1182/bloodadvances.2020004074
  • Song Y, Zhou K, Zou D, et al. Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study. Blood. 2022;139(21):3148–3158. doi:10.1182/blood.2021014162

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.